维布妥昔单抗联合多柔比星和达卡巴嗪治疗非巨块型局限期经典型霍奇金淋巴瘤
本研究评估维布妥昔单抗(BV)联合多柔比星和达卡巴嗪(AD)治疗非巨块型I-II期经典型霍奇金淋巴瘤,根据中期PET反应给予4或6周期。34例患者中总缓解率100%、完全缓解率97%,5年无进展生存率91%;常见不良事件为恶心、周围感觉神经病变和乏力,无4级中性粒细胞减少或中性粒细胞减少性发热。
要点
- BV-AD方案在非巨块型局限期经典型霍奇金淋巴瘤中完全缓解率97%,5年无进展生存率91%。
- 最常见不良事件为恶心(85%)、周围感觉神经病变(59%)和乏力(56%),神经病变多为1级。
- 无4级中性粒细胞减少或中性粒细胞减少性发热,无患者接受粒细胞集落刺激因子。
核心结论
- BV-AD方案产生高完全缓解率和持久无进展生存,多数患者仅需4周期治疗。
- 与BV-AVD相比,毒性特征似乎改善,主要为1级可逆性周围神经病变,无4级中性粒细胞减少或中性粒细胞减少性发热。
- 该方案值得在霍奇金淋巴瘤中进一步研究,并可能作为添加新药的骨架。
研究设计与样本
- 研究纳入34例非巨块型I-II期霍奇金淋巴瘤患者。
- 根据中期正电子发射断层扫描反应,给予4或6周期BV联合AD治疗。
- 风险分组为早期预后良好53%和预后不良47%。
- 试验注册于clinicaltrials.gov(NCT02505269)。
主要发现
- 总缓解率为100%,完全缓解率为97%。
- 5年无进展生存率为91%。
- 基于分期(I vs II)或风险状态(早期预后良好 vs 预后不良)未观察到结局差异。
- 最常见不良事件为恶心(85%)、周围感觉神经病变(59%)和乏力(56%)。
- 无4级中性粒细胞减少或中性粒细胞减少性发热病例,无患者接受粒细胞集落刺激因子;周围神经病变多为1级,无患者发生≥3级周围神经病变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine) with or without radiation has been the standard treatment for limited-stage Hodgkin lymphoma (HL) but carries risks of bleomycin lung injury and radiation toxicity. Brentuximab vedotin (BV) is approved with AVD for stage III-IV HL, but carries increased risks of peripheral neuropathy (PN) and neutropenic fever, likely due to overlapping toxicity between BV and vinblastine. We therefore evaluated BV in combination with AD for 4 or 6 cycles based on interim positron emission tomography response. Thirty-four patients with nonbulky stage I-II HL were enrolled. Risk was early favorable in 53% and unfavorable in 47%. The overall and complete response rates (CRRs) were 100% and 97%, respectively, with a 5-year progression-free survival (PFS) of 91%. No differences in outcome were observed based on stage (I vs II) or risk status (early favorable vs unfavorable). The most common adverse events were nausea (85%), peripheral sensory neuropathy (59%), and fatigue (56%). There were no cases of grade-4 neutropenia or neutropenic fever, and no patient received granulocyte-colony stimulating factor. Most cases of PN were grade 1, and no patient experienced grade ≥3 PN. BV-AD produced a high CRR and durable PFS with most patients requiring 4 cycles of therapy. Compared with BV-AVD, the toxicity profile appeared improved, with predominantly grade 1 reversible PN and no case of grade 4 neutropenia or neutropenic fever. This regimen warrants further study in HL and may serve as a backbone for the addition of novel agents. This trial is registered on clinicaltrials.gov (NCT02505269).
引用
- Abramson JS, Bengston E, Redd R, et al. Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma. Blood Adv. 2023. PMID: 36053786. doi:10.1182/bloodadvances.2022008420
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。